chartexchange

CytoDyn Appoints Lauren Wilcoxen, Ph.D., as Chief Operating Officer and Head of Regulatory Affairs

GlobeNewswire Inc. | Nov 17, 2026 8:30 AM EST

VANCOUVER, Washington, Nov. 17, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY)  ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including colorectal cancer (CRC) and triple-negative breast cancer (TNBC), today announced Lauren Wilcoxen, Ph.D., as its new Chief Operating Officer and Head of Regulatory Affairs, effective November 20, 2026.

Read original article